Certified by Founder
Lodge
Delphia Therapeutics
start up
United States
- Cambridge, Massachusetts
- 07/05/2024
- Series A
- $67,000,000
Delphia Therapeutics is a biotechnology company pioneering activation lethality, a new area of cancer therapeutics that target cancer's surprising vulnerability to oncogene overactivation. Delphia’s activation lethality platform offers the potential for first-in-class targeted cancer medicines that are effective on their own while also combating the emergence of drug resistance to classic targeted therapies.
- Industry Biotechnology Research
- Website https://www.delphiatx.com/
- LinkedIn https://www.linkedin.com/company/delphia-therapeutics/
Lucky Energy | $25,000,000 | (Nov 13, 2025)
Vend Park | $17,500,000 | (Nov 13, 2025)
BoomPop | $41,000,000 | (Nov 13, 2025)
Modulight Biotherapeutics | $12,000,000 | (Nov 13, 2025)
Neros Technologies | $75,000,000 | (Nov 11, 2025)
Uare.ai | $10,300,000 | (Nov 11, 2025)
BITE Data | $2,500,000 | (Nov 11, 2025)
EVE(1) | $2,000,000 | (Nov 11, 2025)
Upward Financial | $8,000,000 | (Nov 11, 2025)
Fastbreak AI | $40,000,000 | (Nov 11, 2025)
The Beans | $5,400,000 | (Nov 11, 2025)
TRIP | $40,000,000 | (Nov 11, 2025)